Product Details
Product Name:
Tremelimumab |
CAS No.:
745013-59-6 |
Purity:
98.7% (SEC-HPLC) |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | Tremelimumab |
Description | Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer. |
In vitro | Tremelimumab exhibits a higher binding affinity for CTLA-4-Ig compared to CD28-Ig, demonstrating specificity for cynomolgus monkeys and humans. It does not engage with human leukocyte FcγR, mitigating the risk of cytokine release syndrome. Interestingly, Tremelimumab enhances IL-2 production in a concentration-dependent manner when stimulated with staphylococcal enterotoxin A, showcasing its ability to modulate T-cell responses.[1] |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Keywords | Tremelimumab | CP675206 | CP 675206 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:704888-90-4
$31.00 / 1mg
-
CAS:64564-03-0
$118.00 / 1mg
-
CAS:645-15-8
$41.00 / 50mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |